Clinical trials: Nephropathy, Diabetic
Diabetic Nephropathy, Chronic Kidney Disease
Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy
Diabetic nephropathy has become the single most frequent cause of end-stage renal disease. On a molecular level, at least five major pathways have been implicated in glucose-mediated vascular and renal damage and all of these…
- Conditions
- Diabetic Nephropathy, Chronic Kidney Disease, Diabetes Type 2
- Trial name
- NCT00556465
- Testing
- N-acetylcysteine
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- Shiraz University of Medical Sciences
Diabetic Kidney Disease
To Improve the Ability of Early Screening and Diagnosis in Patients With Diabetic Nephropathy
This is a large-scale, multi-center, observational study. It is planned to establish a large database of 10,000 patients with type 2 diabetes mellitus to investigate the prevalence, awareness and screening rates of diabetes…
- Trial name
- NCT05047471
- Where
- 50 sites in China
- Volunteers
- 10,000 people
- Sponsor
- Yiming Mu
Chronic Kidney Diseases
Metformin as RenoProtector of Progressive Kidney Disease
A multi-center, practice-oriented, repurposing, double-blinded, placebo-controlled, randomized clinical trial. The RenoMet trial is repurposing an already approved agent (Metformin , Glucophage SR ) in a new indication…
- Trial name
- RenoMet (NCT03831464)
- Testing
- Metformin Hydrochloride
- Where
- 19 sites in Belgium
- Volunteers
- 290 people
- Sponsor
- Universiteit Antwerpen
Diabetic Nephropathy
Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy
Diabetic nephropathy (DN) is one of the most serious complications of diabetes and the leading cause of end-stage chronic kidney disease. DN is a refractory disease with low awareness, high incidence, and high disability.
- Trial name
- UC-MSCs (NCT04562025)
- Testing
- UC-MSCs
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Renmin Hospital of Wuhan University
Diabetic Nephropathies
Effect of Low Protein Diet in Preventing the Progression of Diabetic Nephropathy
Diabetic nephropathy is the leading cause of chronic kidney disease all the world in spite of progress in new treatment for diabetes and anti hypertensive drugs.
- Trial name
- LPD (NCT00448526)
- Testing
- low protein diet
- Sponsor
- Kanazawa Medical University
Diabetes, Kidney Disease
Improving Outcomes in Patients With Kidney Disease Due to Diabetes
Kidney disease affects about one out of three people with diabetes mellitus, a common medical problem. Treatment of kidney disease with medications that lower blood pressure can slow the kidney disease but there is no known cure.
- Conditions
- Diabetes, Kidney Disease, Hypertension
- Trial name
- NCT00381134
- Testing
- losartan 100 mg orally once daily, spironolactone 25 mg orally once daily
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes, Hypertension
Real-world Aliskiren Use in Diabetic Patients
The purpose of this study is to evaluate real-world patterns of aliskiren use with a focus of change in renal function following aliskiren initiation as well as to identify "triggering events" that lead to aliskiren initiation.
- Trial name
- NCT01393860
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Novartis
Diabetic Nephropathies
Effect of High-intensity Laser Exercise Versus Moderate-intensity Aerobic Exercise on Diabetic Polyneuropathy Patients
Diabetic poly neuropathy (DPN) is a length-dependent, symmetrical sensorimotor poly neuropathy and is among the most prevalent and challenging consequences of diabetes4.
- Trial name
- NCT06884462
- Testing
- High-intensity laser (HIL), moderate-intensity aerobic exercise
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Deraya University
Diabetic Kidney Disease, Diabetic Retinopathy
Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy
The purpose of the study is to evaluate the efficacy of Keluoxin Capsules for the treatment of diabetic kidney disease (DKD) and diabetic retinopathy (DR) compared to placebo on a conventional treatment basis.
- Trial name
- NCT06660940
- Testing
- Keluoxin Capsules, Keluoxin Capsule Simulants, Irbesartan
- Volunteers
- 460 people
- Sponsor
- Chinese PLA General Hospital
Glomerulosclerosis, Focal Segmental, Minimal Change Disease
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease.
- Conditions
- Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Diabetic Nephropathies
- Trial name
- NCT04235621
- Testing
- FSGS/TR-MCD, Diabetic Nephropathy (DN)
- Where
- 18 sites in United States
- Volunteers
- 20 people
- Sponsor
- Goldfinch Bio, Inc.
Diabetic Kidney Disease
Oxygen Therapy in Diabetic Kidney Disease
Diabetic kidney disease (DKD) is the most significant cause of end-stage kidney disease (ESKD). Albuminuria, evolving from microalbuminuria to nephrotic-range proteinuria, is a clinical hallmark of diabetic nephropathy (DN).
- Trial name
- NCT06959485
- Testing
- Oxygen Therapy
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Assiut University
Diabetes Mellitus, Type 2, Diabetic Nephropathies
Cholesterol Metabolism in Plasma and Interstitial Fluid Among Subjects Undergoing Hemodialysis.
Because the atherosclerosis process partly occur in the intercellular space of the vessel wall, the determination of the constitution of lipoproteins in the interstitial fluid may expand the knowledge about the atherosclerosis…
- Conditions
- Diabetes Mellitus, Type 2, Diabetic Nephropathies, Chronic Kidney Diseases
- Trial name
- NCT03921216
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Karolinska University Hospital
Diabetes Mellitus, Type 1, Diabetic Nephropathy
Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria
Based upon the preclinical evidence in models of diabetic nephropathy under conditions approximating both type I and II diabetes, treatment with alagebrium appears to have favorable and advantageous effects on the biochemical…
- Trial name
- NCT00557518
- Testing
- Alagebrium
- Where
- 6 sites in Australia, Denmark
- Volunteers
- 80 people
- Sponsor
- Synvista Therapeutics, Inc
Diabetic Nephropathy
Effects of PH3 in Diabetic Nephropathy
The primary objective of this clinical study is to evaluate the effectiveness and safety of PH3 for patients with diabetic nephropathy.
- Trial name
- PH3 (NCT01068041)
- Testing
- PH3
- Where
- 3 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- PhytoHealth Corporation
Serum Cystatin C Before and After Coronary Angiogram, Serum Creatinine Before and After Coronary Angiogram
Limb Ischemic Preconditioning for Prevention of Contrast Media Induced Nephropathy in Diabetic Kidney Patient
Contrast media induced nephropathy (CIN) is considered to be a serious complication in patient who underwent coronary angiogram (CAG). The pathogenesis of CIN does not well understood.
- Trial name
- NCT01763034
- Testing
- limb ischemic preconditioning
- Where
- Thailand
- Volunteers
- 200 people
- Sponsor
- Ramathibodi Hospital
Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease
Proven therapy for DKD is primarily limited to RAAS blockers and SLGT2i. Weight reduction has the potential to become an additional and much needed treatment option.
- Conditions
- Diabetes Mellitus, Type 2, Kidney Disease, Chronic, Kidney Injury
- Trial name
- OBESE-DKD (NCT04626323)
- Testing
- Roux-en-Y gastric bypass, Best medical treatment
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Hospital Alemão Oswaldo Cruz
SGLT2 INHIBITORS, Lupus Nephritis
SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients
The goal of this Randomized, controlled trial in 100 patients with LN with an estimated glomerular filtration rate (eGFR) of 25-75 ml/min/1.73m2.
- Conditions
- SGLT2 INHIBITORS, Lupus Nephritis, BMD
- Trial name
- NCT05704088
- Testing
- Dapagliflozin tablet
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Kidney Diseases
Global Kidney Patient Trials Network
This is a prospective international multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease
- Trial name
- GKPTN (NCT04389827)
- Where
- Australia
- Volunteers
- 5,999 people
- Sponsor
- The George Institute
Diabetic Nephropathy Type 2 - Uncontrolled, Diabetes Mellitus, Type 2
Mixed Methods Study of Health-Related Social Needs in African American Adults With Chronic Kidney Disease and Type 2 Diabetes Mellitus
The overarching goal of this study is to understand facilitators and barriers to self-care, develop and refine a culturally tailored intervention to improve clinical outcomes, quality of life (QOL), and self-care behaviors in…
- Conditions
- Diabetic Nephropathy Type 2 - Uncontrolled, Diabetes Mellitus, Type 2, Chronic Kidney Diseases
- Trial name
- NCT05692388
- Testing
- Patient and Community Stakeholder Interviews, Cross-sectional Study Participants, Focus Groups and Intervention Mapping
- Where
- United States
- Volunteers
- 330 people
- Sponsor
- Medical College of Wisconsin
Proteinuria, Kidney Dysfunction
Azilsartan in Patients With Diabetic Kidney Disease and Hypertension
Hypertension is the most common complication in patients with diabetes nephropathy. Strengthening blood pressure and blood sugar control is the basic treatment for patients with diabetes nephropathy.
- Conditions
- Proteinuria, Kidney Dysfunction, Blood Pressure, Diabetic Kidney Disease
- Trial name
- NCT05753696
- Testing
- Azilsartan, Losartan
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine